Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer

Current Allergy and Asthma Reports

Volumn 8, Issue 1, 2008, Pages 63-68

  Myskowski, Patricia L ^a   Halpern, Allan C ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CAMPATH 1 H; CARBOPLATIN; CETUXIMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; GLUCOCORTICOID; IBRITUMOMAB TIUXETAN; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLATINUM COMPLEX; PREDNISONE; RETINOID; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ANGIONEUROTIC EDEMA; ATOPY; BACTERIAL SUPERINFECTION; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DERMATITIS; DESQUAMATION; DRUG APPROVAL; DRUG BINDING; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EDEMA; ERYTHEMA; FLUSHING; FOLLICULAR LYMPHOMA; HAIR; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; INFLUENZA; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LICHENOID ERUPTION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NAIL; NAUSEA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PAPULAR RASH; PARONYCHIA; PATIENT CARE; PRURITUS; PUSTULE; QUALITY OF LIFE; RASH; REVIEW; RIGOR; SIDE EFFECT; SKIN ALLERGY; SKIN DEFECT; SKIN FISSURE; SKIN INFECTION; SKIN IRRITATION; SKIN NECROSIS; SKIN TOXICITY; SKIN ULCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; URTICARIA; VESICULAR RASH; WOUND HEALING; XEROSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG HYPERSENSITIVITY; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 41549154756     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-008-0012-z     Document Type: Review

References (34)

1. American Cancer Society: Monoclonal antibodies. http://www.cancer.org/docroot/ETO/content/ ETO_1_4X_Monoclonal_Antibody_Therapy_Passive_Immunotherapy.asp. Accessed August 7, 2007.
2. Li Y, Zhu Z: Monoclonal antibody-based therapeutics for leukemia. Expert Opin Biol Ther 2007, 7:319-330.
3. Winter JN: Defining the role of immunotherapy and radiotherapy in the treatment of low-grade lymphoma. Curr Opin Hematol 2007, 14:360-368.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
5. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456-473.
6. Grillo-Lopez E, Hedrich M, Rashford M, Benyunes M: Rituximab: ongoing and future clinical developments. Semin Oncol 2002, 29(Suppl. 2):105-112.
7. Alinari L, Lapalombella, Andritsos L, et al.: Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007, 26:3644-3653.
8. Sievers EL, Larson RA, Stadtmauer EA, et al.: Efficacy and safety of gemtuzumab ozogamacin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244-3254.
9. Gordon LI, Witzig TE, Wiseman GA, et al.: Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol 2002, 29(Suppl 2):87-92.
10. Mylotarg. In: Physicians' Desk Reference, edn 61. Montville, NJ: Thompson PDR; 2007:3433.
11. Ibritumomab: serious cutaneous reactions. Prescrire Int 2006, 15:139.
12. Kaminski MS, Zelenetz AD, Press OW, et al.: Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001, 19:3918-3928.
13. Press OW, Unger JM, Braziel RM, et al.: Phase II trial of CHOP chemotherapy followed by tositimomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006, 24:4143-4149.
14. Hudis CA: Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
15. Nahta R, Esteva FJ: Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643.
16. Laux I, Jain A, Singh S, Agus DA: Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006, 94:85-92.
17. Herceptin. In: Physicians' Desk Reference, edn 61. Montville, NJ: Thompson PDR; 2007:1236
18. Pfeiffer P, Qvortrup C, Eriksen JG: Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007, 26:3661-3678.
19. Gordon MS, Cunningham D: Managing patient treated with bevacizumab combination therapy. Oncology 2005, 69(Suppl 3):25-33.
20. Gotlib V, Khaled S, Lapko I, et al.: Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and the relation to response. Anticancer Drugs 2006, 17:1227-1229.
21. Scappaticci FA, Fehrenbacher L, Cartwright T, et al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91:173-180.
22. Kabbinavar F, Hurwitz HI, Febrenbacher L, et al.: Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
23. Saltz LB, Meropol NJ, Loehrer PJ, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor. J Clin Oncol 2004, 22:1201-1208.
24. Karamouzis MV, Grandis JR, Argiris A: Therapies directed against the epidermal growth factor in aerodigestive carcinomas. JAMA 2007, 298:70-82.
25. Cunninghan D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
26. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
27. Saif MW, Kim R: Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007, 6:175-182.
28. O'Neill BH, Allen RA, Spigel DR, et al.: High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007, 25:3644-3648.
29. Budach W, Bolke E, Homey B: Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007, 357:514-515.
30. Perez-Soler R, Delord JP, Halpern A, et al.: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005, 10:345-356.
31. Agero AL, Dusza SW, Benvenuto-Andrade C, et al.: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006, 55:657-670.
32. Perez-Soler R, Saltz L: Cutaneous adverse effects with HER1-EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005, 23:5235-5246.
33. Van Cutsem E, Peeters M, Siena S, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
34. Giustri RM, Shastri KA, Cohen MH, et al.: FDA drug approval summary: panitumumab (Vectibix). Oncologist 2007, 12:577-583.